Sioux Pharm, Inc. v. Eagle Labs., Inc.

by
In this battle between two domestic producers of chondroitin sulfate, Plaintiffs filed suit claiming trade-secrets violations against Defendants. Before the Supreme Court was an interlocutory appeal on a discovery issue. The district court entered a protective order requiring the redesignation of Plaintiffs’ standard operating procedures from “attorneys’ eyes only” to “confidential,” which would allow these materials to be disclosed to the defendants themselves. The Supreme Court reversed, holding that, while removing the “attorneys’ eyes only” designation may have been appropriate, the district court’s rationale for ordering redesignation was insufficient. Remanded for further consideration. View "Sioux Pharm, Inc. v. Eagle Labs., Inc." on Justia Law